샘플 요청 목록

 카트 문의
시장보고서
상품코드
2021158

콜리스틴 시장 규모 및 예측(2021-2034년) : 세계 및 지역별 점유율, 동향, 성장 기회 분석 리포트 범위 - 제형, 적응증, 유통 채널 및 지역별

Colistin Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Formulation, Indication, Distribution Channel, and Geography
발행일: | 리서치사: 구분자 The Insight Partners | 페이지 정보: 영문 346 Pages | 배송안내 : 즉시배송

    
    
    



가격
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.
US $ 4,450 금액 안내 화살표 ￦ 6,775,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,450 금액 안내 화살표 ￦ 9,820,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,450 금액 안내 화살표 ￦ 12,865,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

콜리스틴 시장 규모는 2025년 3억 3,700만 달러에서 2034년까지 5억 1,094만 달러로 확대할 것으로 예상되고 있으며, 2026-2034년에 CAGR 4.8%를 기록할 것으로 전망되고 있습니다. 헬스케어 분야에서 다제내성 그람음성균 감염의 증가와 가축 및 가금류 사육에 대한 수의학적 수요의 지속적 증가는 콜리스틴 시장 확대에 기여하는 주목할 만한 요인으로 꼽힙니다. 또한 새로운 제형과 전달 시스템의 발전, 그리고 병용요법 및 시너지 요법의 증가는 가까운 미래에 시장에 새로운 동향을 가져올 것으로 예상됩니다.

새로운 제형 및 전달 시스템의 발전에는 특히 전신 감염 질환에서 약물을 인캡슐레이션하여 신독성을 줄이고 표적에 대한 전달성을 향상시키는 리포솜형 콜리스틴의 개발이 포함됩니다. 예를 들어 기존 주사제를 넘어 치료 옵션을 확대하기 위해 리포좀 제제가 검토되고 있으며, 호흡기 감염이나 국소 감염에 대해는 흡입제나 외용제가 주목받고 있습니다. 2022년에 시작된 대규모 임상 시험에서 새로운 콜리스틴 제제를 병용요법으로 평가한 결과, 중증 환자에서 치료 효과가 개선된 것으로 나타났습니다. 고순도 코리스틴 황산염 부문은 치료 및 연구 용도에 힘입어 주요 점유율을 차지하고 있습니다. 만성 폐 감염의 경우, 2023년 전 세계에서 분무기 및 국소 투여를 통한 코리스틴의 임상시험이 증가하고 있으며, 낭포성 섬유증, 인공호흡기 관련 폐렴 등의 질환에 초점을 맞추고 있습니다. 나노테크놀러지의 발전은 콜리스틴의 활성을 높이고 약물의 침투성을 향상시켜 내성 발생 가능성을 줄이는 데 중점을 두고 있습니다. 이러한 혁신은 대체 수단이 제한적인 틈새 시장에서 수요를 유지할 것으로 예상되며, 특히 아시아태평양과 같이 감염 부담이 높은 지역에서 의료 인프라가 확대됨에 따라 큰 점유율을 차지할 것으로 예상됩니다. 또한 내성균주에 대한 콜리스틴의 효과를 높이기 위해 보조요법으로 광선역학요법(PDT)이 도입되고 있습니다. 전반적으로 독성 감소, 생물학적 이용률 향상, 다제내성 감염에 대한 효능 강화를 목표로 하는 새로운 제제 및 전달 시스템의 혁신이 향후 수년간 주요 동향이 될 것으로 예상됩니다.

유통 채널별 인사이트

유통 채널에 따라 콜리스틴 시장은 병원 약국, 소매 약국, 온라인 채널 및 기타 유통 채널로 분류됩니다. 2025년에는 병원 약국 부문이 가장 큰 시장 점유율을 차지했습니다. 병원 약국은 헬스케어 분야에서 콜리스틴의 주요 유통 채널로서, 특히 중환자실(ICU) 환경에서 심각한 다제내성 그람음성균 감염을 치료하는 데 중요한 역할을 하고 있습니다. 인공호흡기 관련 폐렴, 패혈증 등의 질환에 이 약물을 정맥주사 또는 흡입투여합니다. 예를 들어 콜리스틴메탄설포네이트는 아시네토박터 바우마니, 녹농균 등의 병원균에 대한 최후의 수단으로 병원 처방집에 일반적으로 등재되어 있으며, 신독성을 줄이기 위해 신기능에 따라 투여 프로토콜이 조정되어 있습니다. 2023년, 병원 약제부는 폴리믹신계 항생제가 필요한 320만 건 이상의 중환자실 관련 감염 치료를 지원했습니다. 브라질, 인도네시아, 러시아 등의 국가에서는 중증 환자의 37% 이상이 카르바페넴계 항생제 내성을 보이고 있으며, 이것이 수요를 견인하고 있습니다. 한 연구에 따르면 인체용 의약품에서 콜리스틴 유통의 약 60%는 병원 경로를 통해 이루어지고 있으며, Xellia Pharmaceuticals 및 Fresenius Kabi와 같은 제조업체로부터 직접 조달을 통해 이루어지고 있다고 합니다. 병원에서는 병용요법 채택이 증가하고 있으며, 이로 인해 유효성이 향상되는 한편, 약제 적정사용 프로그램을 통해 사용 현황을 모니터링하고 내성균 발생을 억제하고 있습니다. 유럽에서는 유럽의약품청(EMA)이 병원 공급을 규제하고 있으며, 고순도 제제가 확보되어 있습니다. 히쿠마 파마슈티컬스, 테바 파마슈티컬 인더스트리즈와 같은 주요 기업은 계약에 기반한 제휴를 통해 공급하고 있으며, 규제 프레임워크 내에서 공급망의 탄력성을 중요시하고 있습니다. 이 채널이 지배적인 이유는 콜리스틴이 급성기 의료에서 중요한 역할을 하기 때문이지만, 독성에 대한 우려로 인해 외래 진료로 광범위하게 전환하는 것은 제한적입니다.

목차

제1장 개요

제2장 콜리스틴 시장 구도

제3장 경쟁 구도

제4장 콜리스틴 시장 - 주요 업계 동향

제5장 콜리스틴 시장 - 세계 시장 분석

제6장 콜리스틴 시장의 매출 분석 - 제형별

제7장 콜리스틴 시장의 매출 분석 - 적응증별

제8장 콜리스틴 시장의 매출 분석 - 유통 채널

제9장 콜리스틴 시장 - 지역 분석

제10장 콜리스틴 시장의 업계 상황

제11장 콜리스틴 시장 - 주요 기업 개요

제12장 부록

KSA 26.05.12

The Colistin market size is expected to grow from US$ 337.00 million in 2025 to US$ 510.94 million by 2034; it is projected to register a CAGR of 4.8% during 2026-2034. The increased multidrug-resistant Gram-negative infections in human healthcare, sustained veterinary demand in livestock and poultry farming are noteworthy factors contributing to the expansion of the colistin market. Additionally, the advancements in novel formulations and delivery systems as well as a rise in combination and synergistic therapies are projected to bring new market drifts in the near future.

The advancement in novel formulations and delivery systems includes the development of liposomal colistin, which encapsulates the drug to reduce nephrotoxicity and improve targeted delivery, particularly for systemic infections. For instance, liposomal formulations are being explored to broaden treatment options beyond traditional injectables, with inhalable and topical preparations gaining traction for respiratory and localized infections. A large-scale clinical trial launched in 2022 evaluated novel colistin formulations in combination therapies, demonstrating improved outcomes in severe cases. The high-purity colistin sulfate segment holds a major share, driven by therapeutic and research applications. In chronic lung infections, nebulized and topical colistin delivery experienced an increase in global clinical trials in 2023, focusing on conditions such as cystic fibrosis and ventilator-associated pneumonia. Advancements in nanotechnology are focused on enhancing colistin's activity, reducing the likelihood of resistance through improved drug penetration. These innovations are expected to sustain demand in niche applications where alternatives are limited, particularly in high-burden regions such as Asia Pacific, which anticipates a major share owing to expanding healthcare infrastructure. Photodynamic therapy (PDT) as an adjunctive method is also being integrated to boost colistin's effectiveness against resistant strains. Overall, innovations in novel formulations and delivery systems aimed at minimizing toxicity, improving bioavailability, and enhancing efficacy against multidrug-resistant infections are expected to be the key trends in the coming years.

Distribution Channel -Based Insights

Based on distribution channel, the colistin market is segmented into hospital pharmacy, retail pharmacy, online channel, and other distribution channel. The hospital pharmacy segment held the largest market share in 2025. Hospital pharmacies serve as the primary distribution channel for colistin in human healthcare, particularly for treating severe multidrug-resistant Gram-negative infections in intensive care settings, where the drug is administered intravenously or via inhalation for conditions like ventilator-associated pneumonia and sepsis. For example, colistin methanesulfonate is commonly stocked in hospital formularies for last-resort use against pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, with dosing protocols adjusted for renal function to mitigate nephrotoxicity. In 2023, hospital pharmacies facilitated treatments for over 3.2 million ICU-related infections requiring polymyxin-class antibiotics, with countries like Brazil, Indonesia, and Russia reporting over 37% of severe cases resistant to carbapenems, driving demand. A study indicated that hospital channels account for approximately 60% of colistin distribution in human medicine, supported by direct procurement from manufacturers like Xellia Pharmaceuticals and Fresenius Kabi. Trends show increasing adoption of combination therapies in hospitals, enhancing efficacy while stewardship programs monitor usage to curb resistance. In Europe, the European Medicines Agency regulates hospital supplies, ensuring high-purity formulations. Key players such as Hikma Pharmaceuticals and Teva Pharmaceutical Industries supply through contractual collaborations, emphasizing supply chain resilience amid regulatory frameworks. This channel's dominance stems from colistin's role in acute care, though toxicity concerns limit broader outpatient shifts.

The World Health Organization, Centers for Disease Control and Prevention (CDC), Pan-Canadian Action Plan on Antimicrobial Resistance, European Centre for Disease Prevention and Control (ECDC), UK Health Security Agency (UKHSA), Agency for Health and Food Safety, the National Public Health Organization, Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report, the Australia and New Zealand Group on Antimicrobial Resistance (AGAR), the Ministry of Health, and Labour and Welfare (MHLW) are among the primary and secondary sources referred to while preparing the colistin market report.

Table Of Contents

1. Executive Summary

  • 1.1 Analyst Market Outlook
  • 1.2 Market Attractiveness

2. Colistin Market Landscape

  • 2.1 Overview
  • 2.2 Value Chain Analysis
    • 2.2.1 Raw Material Suppliers / Components
    • 2.2.2 Manufacturers/ Process / Technology
    • 2.2.3 Distribution Landscape
    • 2.2.4 End User
    • 2.2.5 Level of Integration
  • 2.3 Supply Chain Analysis
    • 2.3.1 List of Manufacturers/Suppliers
    • 2.3.2 List of Potential Customers (Upto 50)
  • 2.4 Porter's Five Force Analysis
    • 2.4.1 Bargaining Power of Suppliers: Moderate
    • 2.4.2 Bargaining Power of Buyers: High
    • 2.4.3 Threat of New Entrants: Moderate
    • 2.4.4 Threat of Substitutes: High
    • 2.4.5 Competitive Rivalry: High
  • 2.5 PEST Analysis
  • 2.6 Sustainability and ESG Trends
    • 2.6.1 Sustainability Trends
    • 2.6.2 Environmental Trends
    • 2.6.3 Social Trends
    • 2.6.4 Governance Trends
  • 2.7 Regulatory Framework
  • 2.8 Market Entry Barriers
    • 2.8.1 Regulatory Aspect
    • 2.8.2 Competitive Aspect
    • 2.8.3 Reimbursement-Related Aspect
  • 2.9 CMS Vs Colistin Base Sulphate - Manufacturing & Commercial Assessment
  • 2.10 Global Tender Analysis
  • 2.11 Prevalence of Key 3 Diseases, By Region, 2024
  • 2.12 Pricing Analysis, ASPs of Key Products
  • 2.13 Global Colistin API Market Volume (Tonnes), 2025
  • 2.14 Pipeline Analysis of Next-Generation Polymyxins

3. Competitive Landscape

  • 3.1 Company Benchmarking by Key Players
  • 3.2 Market Share Analysis (%), 2025
  • 3.3 Market Concentration

4. Colistin Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increased Multidrug-Resistant Gram-Negative Infections in Human Healthcare:
    • 4.1.2 Sustained Veterinary Demand in Livestock and Poultry Farming
    • 4.1.3 Regulatory Shifts and Policies Addressing Antimicrobial Resistance
  • 4.2 Market Restraints
    • 4.2.1 Limiting Clinical Adoption
    • 4.2.2 Increased Prevalence of Colistin Resistance
    • 4.2.3 Stringent Regulatory Policies and Bans
  • 4.3 Market Opportunities
    • 4.3.1 Advancements in Inhaled Colistin Formulations for Respiratory Infections
    • 4.3.2 Expansion of Combination Therapies for Multidrug-Resistant Infections
    • 4.3.3 Regional Market Expansion in Asia Pacific Amid Rising Antimicrobial Resistance
  • 4.4 Future Trends
    • 4.4.1 Advancements in Novel Formulations and Delivery Systems
    • 4.4.2 Rise in Combination and Synergistic Therapies
    • 4.4.3 Enhanced Antimicrobial Stewardship and Regulatory Frameworks
  • 4.5 Impact of Drivers and Restraints

5. Colistin Market - Global Market Analysis

  • 5.1 Colistin Market Revenue (US$ Million), 2021-2034
  • 5.2 Colistin Market Forecast and Analysis

6. Colistin Market Revenue Analysis - Formulation

  • 6.1 Colistin Market Forecasts and Analysis by Formulation
    • 6.1.1 Oral
      • 6.1.1.1 Overview
      • 6.1.1.2 Oral: Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.2 Injectables (IV or IM)
      • 6.1.2.1 Overview
      • 6.1.2.2 Injectables (IV or IM): Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.3 Topical Formulations
      • 6.1.3.1 Overview
      • 6.1.3.2 Topical Formulations: Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.4 Inhalation Solutions
      • 6.1.4.1 Overview
      • 6.1.4.2 Inhalation Solutions: Colistin Market - Revenue, 2021-2034 (US$ Million)

7. Colistin Market Revenue Analysis - Indication

  • 7.1 Colistin Market Forecasts and Analysis by Indication
    • 7.1.1 Animal Health
      • 7.1.1.1 Overview
      • 7.1.1.2 Animal Health Health: Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 7.1.2 Human Health
      • 7.1.2.1 Overview
      • 7.1.2.2 Human Health: Colistin Market - Revenue, 2021-2034 (US$ Million)

8. Colistin Market Revenue Analysis - Distribution Channel

  • 8.1 Colistin Market Forecasts and Analysis by Distribution Channel
    • 8.1.1 Hospital Pharmacy
      • 8.1.1.1 Overview
      • 8.1.1.2 Hospital Pharmacy: Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 8.1.2 Retail Pharmacy
      • 8.1.2.1 Overview
      • 8.1.2.2 Retail Pharmacy: Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 8.1.3 Online Channel
      • 8.1.3.1 Overview
      • 8.1.3.2 Online Channel: Colistin Market - Revenue, 2021-2034 (US$ Million)
    • 8.1.4 Other Distribution Channel
      • 8.1.4.1 Overview
      • 8.1.4.2 Other Distribution Channel: Colistin Market - Revenue, 2021-2034 (US$ Million)

9. Colistin Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Colistin Market Overview
    • 9.1.2 North America: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.1.3 North America: Colistin Market - By Segmentation
      • 9.1.3.1 Formulation
      • 9.1.3.2 Indication
        • 9.1.3.2.1 Human Health
      • 9.1.3.3 Distribution Channel
    • 9.1.4 North America: Colistin Market Breakdown by Countries
      • 9.1.4.1 United States Market
        • 9.1.4.1.1 United States: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.1.4.1.2 United States: Colistin Market - By Segmentation
          • 9.1.4.1.2.1 Formulation
          • 9.1.4.1.2.2 Indication
            • 9.1.4.1.2.2.1 Human Health
          • 9.1.4.1.2.3 Distribution Channel
      • 9.1.4.2 Canada Market
        • 9.1.4.2.1 Canada: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.1.4.2.2 Canada: Colistin Market - By Segmentation
          • 9.1.4.2.2.1 Formulation
          • 9.1.4.2.2.2 Indication
            • 9.1.4.2.2.2.1 Human Health
          • 9.1.4.2.2.3 Distribution Channel
      • 9.1.4.3 Mexico Market
        • 9.1.4.3.1 Mexico: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.1.4.3.2 Mexico: Colistin Market - By Segmentation
          • 9.1.4.3.2.1 Formulation
          • 9.1.4.3.2.2 Indication
            • 9.1.4.3.2.2.1 Human Health
          • 9.1.4.3.2.3 Distribution Channel
  • 9.2 Europe
    • 9.2.1 Europe Colistin Market Overview
    • 9.2.2 Europe: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.2.3 Europe: Colistin Market - By Segmentation
      • 9.2.3.1 Formulation
      • 9.2.3.2 Indication
        • 9.2.3.2.1 Human Health
      • 9.2.3.3 Distribution Channel
    • 9.2.4 Europe: Colistin Market Breakdown by Countries
      • 9.2.4.1 Germany Market
        • 9.2.4.1.1 Germany: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.1.2 Germany: Colistin Market - By Segmentation
          • 9.2.4.1.2.1 Formulation
          • 9.2.4.1.2.2 Indication
            • 9.2.4.1.2.2.1 Human Health
          • 9.2.4.1.2.3 Distribution Channel
      • 9.2.4.2 United Kingdom Market
        • 9.2.4.2.1 United Kingdom: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.2.2 United Kingdom: Colistin Market - By Segmentation
          • 9.2.4.2.2.1 Formulation
          • 9.2.4.2.2.2 Indication
            • 9.2.4.2.2.2.1 Human Health
          • 9.2.4.2.2.3 Distribution Channel
      • 9.2.4.3 France Market
        • 9.2.4.3.1 France: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.3.2 France: Colistin Market - By Segmentation
          • 9.2.4.3.2.1 Formulation
          • 9.2.4.3.2.2 Indication
            • 9.2.4.3.2.2.1 Human Health
          • 9.2.4.3.2.3 Distribution Channel
      • 9.2.4.4 Italy Market
        • 9.2.4.4.1 Italy: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.4.2 Italy: Colistin Market - By Segmentation
          • 9.2.4.4.2.1 Formulation
          • 9.2.4.4.2.2 Indication
            • 9.2.4.4.2.2.1 Human Health
          • 9.2.4.4.2.3 Distribution Channel
      • 9.2.4.5 Spain Market
        • 9.2.4.5.1 Spain: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.5.2 Spain: Colistin Market - By Segmentation
          • 9.2.4.5.2.1 Formulation
          • 9.2.4.5.2.2 Indication
            • 9.2.4.5.2.2.1 Human Health
          • 9.2.4.5.2.3 Distribution Channel
      • 9.2.4.6 Poland Market
        • 9.2.4.6.1 Poland: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.6.2 Poland: Colistin Market - By Segmentation
          • 9.2.4.6.2.1 Formulation
          • 9.2.4.6.2.2 Indication
            • 9.2.4.6.2.2.1 Human Health
          • 9.2.4.6.2.3 Distribution Channel
      • 9.2.4.7 Romania Market
        • 9.2.4.7.1 Romania: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.7.2 Romania: Colistin Market - By Segmentation
          • 9.2.4.7.2.1 Formulation
          • 9.2.4.7.2.2 Indication
            • 9.2.4.7.2.2.1 Human Health
          • 9.2.4.7.2.3 Distribution Channel
      • 9.2.4.8 Serbia Market
        • 9.2.4.8.1 Serbia: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.8.2 Serbia: Colistin Market - By Segmentation
          • 9.2.4.8.2.1 Formulation
          • 9.2.4.8.2.2 Indication
            • 9.2.4.8.2.2.1 Human Health
          • 9.2.4.8.2.3 Distribution Channel
      • 9.2.4.9 Bulgaria Market
        • 9.2.4.9.1 Bulgaria: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.9.2 Bulgaria: Colistin Market - By Segmentation
          • 9.2.4.9.2.1 Formulation
          • 9.2.4.9.2.2 Indication
            • 9.2.4.9.2.2.1 Human Health
          • 9.2.4.9.2.3 Distribution Channel
      • 9.2.4.10 Czech Republic Market
        • 9.2.4.10.1 Czech Republic: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.10.2 Czech Republic: Colistin Market - By Segmentation
          • 9.2.4.10.2.1 Formulation
          • 9.2.4.10.2.2 Indication
            • 9.2.4.10.2.2.1 Human Health
          • 9.2.4.10.2.3 Distribution Channel
      • 9.2.4.11 Belgium Market
        • 9.2.4.11.1 Belgium: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.11.2 Belgium: Colistin Market - By Segmentation
          • 9.2.4.11.2.1 Formulation
          • 9.2.4.11.2.2 Indication
            • 9.2.4.11.2.2.1.1 Human Health
          • 9.2.4.11.2.3 Distribution Channel
      • 9.2.4.12 Slovakia Market
        • 9.2.4.12.1 Slovakia: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.12.2 Slovakia: Colistin Market - By Segmentation
          • 9.2.4.12.2.1 Formulation
          • 9.2.4.12.2.2 Indication
            • 9.2.4.12.2.2.1 Human Health
          • 9.2.4.12.2.3 Distribution Channel
      • 9.2.4.13 Ireland Market
        • 9.2.4.13.1 Ireland: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.13.2 Ireland: Colistin Market - By Segmentation
          • 9.2.4.13.2.1 Formulation
          • 9.2.4.13.2.2 Indication
            • 9.2.4.13.2.2.1 Human Health
          • 9.2.4.13.2.3 Distribution Channel
      • 9.2.4.14 Hungary Market
        • 9.2.4.14.1 Hungary: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.14.2 Hungary: Colistin Market - By Segmentation
          • 9.2.4.14.2.1 Formulation
          • 9.2.4.14.2.2 Indication
            • 9.2.4.14.2.2.1 Human Health
          • 9.2.4.14.2.3 Distribution Channel
      • 9.2.4.15 Portugal Market
        • 9.2.4.15.1 Portugal: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.15.2 Portugal: Colistin Market - By Segmentation
          • 9.2.4.15.2.1 Formulation
          • 9.2.4.15.2.2 Indication
            • 9.2.4.15.2.2.1 Human Health
          • 9.2.4.15.2.3 Distribution Channel
      • 9.2.4.16 Lithuania Market
        • 9.2.4.16.1 Lithuania: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.16.2 Lithuania: Colistin Market - By Segmentation
          • 9.2.4.16.2.1 Formulation
          • 9.2.4.16.2.2 Indication
            • 9.2.4.16.2.2.1 Human Health
          • 9.2.4.16.2.3 Distribution Channel
      • 9.2.4.17 Austria Market
        • 9.2.4.17.1 Austria: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.17.2 Austria: Colistin Market - By Segmentation
          • 9.2.4.17.2.1 Formulation
          • 9.2.4.17.2.2 Indication
            • 9.2.4.17.2.2.1 Human Health
          • 9.2.4.17.2.3 Distribution Channel
      • 9.2.4.18 Bosnia Market
        • 9.2.4.18.1 Bosnia: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.18.2 Bosnia: Colistin Market - By Segmentation
          • 9.2.4.18.2.1 Formulation
          • 9.2.4.18.2.2 Indication
            • 9.2.4.18.2.2.1 Human Health
          • 9.2.4.18.2.3 Distribution Channel
      • 9.2.4.19 Latvia Market
        • 9.2.4.19.1 Latvia: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.19.2 Latvia: Colistin Market - By Segmentation
          • 9.2.4.19.2.1 Formulation
          • 9.2.4.19.2.2 Indication
            • 9.2.4.19.2.2.1 Human Health
          • 9.2.4.19.2.3 Distribution Channel
      • 9.2.4.20 Netherlands Market
        • 9.2.4.20.1 Netherlands: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.20.2 Netherlands: Colistin Market - By Segmentation
          • 9.2.4.20.2.1 Formulation
          • 9.2.4.20.2.2 Indication
            • 9.2.4.20.2.2.1 Human Health
          • 9.2.4.20.2.3 Distribution Channel
      • 9.2.4.21 Greece Market
        • 9.2.4.21.1 Greece: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.21.2 Greece: Colistin Market - By Segmentation
          • 9.2.4.21.2.1 Formulation
          • 9.2.4.21.2.2 Indication
            • 9.2.4.21.2.2.1 Human Health
          • 9.2.4.21.2.3 Distribution Channel
      • 9.2.4.22 Rest of Europe Market
        • 9.2.4.22.1 Rest of Europe: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.22.2 Rest of Europe: Colistin Market - By Segmentation
          • 9.2.4.22.2.1 Formulation
          • 9.2.4.22.2.2 Indication
            • 9.2.4.22.2.2.1 Human Health
          • 9.2.4.22.2.3 Distribution Channel
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Colistin Market Overview
    • 9.3.2 Asia Pacific: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.3.3 Asia Pacific: Colistin Market - By Segmentation
      • 9.3.3.1 Formulation
      • 9.3.3.2 Indication
        • 9.3.3.2.1 Human Health
      • 9.3.3.3 Distribution Channel
    • 9.3.4 Asia Pacific: Colistin Market Breakdown by Countries
      • 9.3.4.1 Australia and New Zealand Market
        • 9.3.4.1.1 Australia and New Zealand: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.1.2 Australia and New Zealand: Colistin Market - By Segmentation
          • 9.3.4.1.2.1 Formulation
          • 9.3.4.1.2.2 Indication
            • 9.3.4.1.2.2.1 Human Health
          • 9.3.4.1.2.3 Distribution Channel
      • 9.3.4.2 Japan Market
        • 9.3.4.2.1 Japan: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.2.2 Japan: Colistin Market - By Segmentation
          • 9.3.4.2.2.1 Formulation
          • 9.3.4.2.2.2 Indication
            • 9.3.4.2.2.2.1 Human Health
          • 9.3.4.2.2.3 Distribution Channel
      • 9.3.4.3 Kazakhstan Market
        • 9.3.4.3.1 Kazakhstan: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.3.2 Kazakhstan: Colistin Market - By Segmentation
          • 9.3.4.3.2.1 Formulation
          • 9.3.4.3.2.2 Indication
            • 9.3.4.3.2.2.1 Human Health
          • 9.3.4.3.2.3 Distribution Channel
      • 9.3.4.4 Rest of APAC Market
        • 9.3.4.4.1 Rest of APAC: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.4.2 Rest of APAC: Colistin Market - By Segmentation
          • 9.3.4.4.2.1 Formulation
          • 9.3.4.4.2.2 Indication
            • 9.3.4.4.2.2.1 Human Health
          • 9.3.4.4.2.3 Distribution Channel
  • 9.4 Middle East and Africa
    • 9.4.1 Middle East and Africa Colistin Market Overview
    • 9.4.2 Middle East and Africa: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.4.3 Middle East and Africa: Colistin Market - By Segmentation
      • 9.4.3.1 Formulation
      • 9.4.3.2 Indication
        • 9.4.3.2.1 Human Health
      • 9.4.3.3 Distribution Channel
    • 9.4.4 Middle East and Africa: Colistin Market Breakdown by Countries
      • 9.4.4.1 Saudi Arabia Market
        • 9.4.4.1.1 Saudi Arabia: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.4.4.1.2 Saudi Arabia: Colistin Market - By Segmentation
          • 9.4.4.1.2.1 Formulation
          • 9.4.4.1.2.2 Indication
            • 9.4.4.1.2.2.1 Human Health
          • 9.4.4.1.2.3 Distribution Channel
      • 9.4.4.2 Rest of Middle East and Africa Market
        • 9.4.4.2.1 Rest of Middle East and Africa: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.4.4.2.2 Rest of Middle East and Africa: Colistin Market - By Segmentation
          • 9.4.4.2.2.1 Formulation
          • 9.4.4.2.2.2 Indication
            • 9.4.4.2.2.2.1 Human Health
          • 9.4.4.2.2.3 Distribution Channel
  • 9.5 South and Central America
    • 9.5.1 South and Central America Colistin Market Overview
    • 9.5.2 South and Central America: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.5.3 South and Central America: Colistin Market - By Segmentation
      • 9.5.3.1 Formulation
      • 9.5.3.2 Indication
        • 9.5.3.2.1 Human Health
      • 9.5.3.3 Distribution Channel
    • 9.5.4 South and Central America: Colistin Market Breakdown by Countries
      • 9.5.4.1 Brazil Market
        • 9.5.4.1.1 Brazil: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.5.4.1.2 Brazil: Colistin Market - By Segmentation
          • 9.5.4.1.2.1 Formulation
          • 9.5.4.1.2.2 Indication
            • 9.5.4.1.2.2.1 Human Health
          • 9.5.4.1.2.3 Distribution Channel
      • 9.5.4.2 Rest of South and Central America Market
        • 9.5.4.2.1 Rest of South and Central America: Colistin Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.5.4.2.2 Rest of South and Central America: Colistin Market - By Segmentation
          • 9.5.4.2.2.1 Formulation
          • 9.5.4.2.2.2 Indication
            • 9.5.4.2.2.2.1 Human Health
          • 9.5.4.2.2.3 Distribution Channel

10. Colistin Market Industry Landscape

11. Colistin Market - Key Company Profiles

  • 11.1 Hebei Shengxue Dacheng Pharmaceutical Co., Ltd
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Norma Hellas S.A
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Apeloa Pharmaceutical Co., Ltd.
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Livzon Pharmaceutical Group Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Shandong LuKang Pharmaceutical Co., Ltd
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Xellia Pharmaceuticals ApS
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Zhejiang Shenghua Biok Chemical Company Limited
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Fujian lifecome biochemistry Limited
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Tecoland Corporation
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 TZF Polfa S.A.
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 Glossary
  • 12.2 Research Methodology and Approach
    • 12.2.1 Secondary Research
    • 12.2.2 Primary Research
    • 12.2.3 Market Estimation Approach
      • 12.2.3.1 Supply Side Analysis
      • 12.2.3.2 Demand Side Analysis
    • 12.2.4 Research Assumptions and Limitations
    • 12.2.5 Currency Conversion
  • 12.3 About The Insight Partners
  • 12.4 Market Intelligence Cloud
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기